Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
This is a phase II study of taxotere, cisplatin and irinotecan (CPT-11) used in combination
to treat metastatic esophageal and gastric cancer in an effort to see what effects (good and
bad) the combination may have on the patients cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Aventis Pharmaceuticals Beth Israel Deaconess Medical Center Brigham and Women's Hospital Massachusetts General Hospital